OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research
The non-profit consortium is developing publicly accessible advanced drug discovery software tools
OpenFold, a consortium of academic and industry partners founded in
“This growth in membership continues the momentum generated after the formation of the consortium, as well as the introduction of the first Consortium-released protein structure prediction AI model developed in Dr. Mohammed AlQuraishi’s laboratory, both in June of this year,” said
“At Bayer, we are driving innovation and transformation. We are excited to be partners with OpenFold, where we can work with leading experts across industries to develop the best methodologies for pharmaceutical and agricultural product design. By computationally simplifying our discovery process, we can increase the speed and quality of product design,” said Dr.
“By joining the growing OpenFold community we are excited to strengthen the use of AI in our discovery solution experiences."
OpenFold’s mission is to bring the most powerful software ever created -- AI systems with the ability to engineer the molecules of life -- to everyone. These tools can be used by academics, biotech and pharmaceutical companies, or students learning to create the medicines of tomorrow, to accelerate basic biological research, and bring new cures to market that would be impossible to discover without AI.
OpenFold is a non-profit artificial intelligence (AI) research consortium of academic and industry partners whose goal is to develop free and open-source software tools for biology and drug discovery, hosted as a project of the
Press and membership inquiries should be directed to firstname.lastname@example.org.